Value in Health Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• EE116 Predicting High-Cost Diabetes Patients: An Analysis of Commercially-Insured Population.  26:s80-s81. 2023
• HPR110 Risk Factors Associated with Repeat Pediatric Asthma Visits to Emergency Departments.  26:s230-S230. 2023
• PCR173 Predictors of Pediatric Emergency Department (ED) Visits for the Acute Ambulatory Care Sensitive Conditions (ACSC).  26:s344-S344. 2023
• Are We Ready for a New Approach to Comparing Coverage and Reimbursement Policies for Medical Nutrition in Key Markets: An ISPOR Special Interest Group Report..  25:677-684. 2022
• EE459 Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2- Advanced Breast Cancer - a US Payer Perspective Cost-Utility Analysis.  25:s425-S425. 2022
• HT2 Evaluation of Tucatinib for HER2-Positive Breast Cancer Patients with Brain Metastases: A United States-Based Cost-Effectiveness Analysis.  24:s9-S9. 2021
• PSU5 Liposomal Bupivacaine and Inpatient Hospital Costs after Colorectal Surgery.  24:s224-S224. 2021
• PDB78 RACIAL DIFFERENCES IN HEALTHCARE COSTS ASSOCIATED WITH OBESITY-RELATED MULTI-MORBIDITY IN THE UNITED STATES.  23:S122-S123. 2020
• Medical Nutrition Terminology and Regulations in the United States and Europe-A Scoping Review: Report of the ISPOR Nutrition Economics Special Interest Group..  22:1-12. 2019
• PRM57 Classification of Causes of Hospitalization For Heart Failure Patients In Cost-Effectiveness and Cost-Utility Evaluations of Pharmacotherapeutic, Surgical, and Managed-Care Interventions: Systematic Review.  20:a740-A740. 2017
• PND37 Patient preferences for attributes of disease modifying Therapies: Results of a choice based conjoint analysis.  16:a107-A107. 2013
• PCN72 Cost Effectiveness Analysis of New Treatments for Metastatic Castration-Resistant Prostate Cancer: Does Severity Matter?.  15:a220-a221. 2012
• PND3 The Population-Based Impact of MS in Asia.  15:a675-A675. 2012
• Patient-reported Pediatric Quality of Life Inventory 4.0 Generic Core Scales in pediatric patients with attention-deficit/hyperactivity disorder and comorbid psychiatric disorders: feasibility, reliability, and validity..  14:521-530. 2011
• AGE-SPECIFIC ORIGINALS: USING THE PEDIATRIC QUALITY OF LIFE T (PEDSQL (TM)) DIABETES MODULE TO STUDY SIMILARITIES AND DIFFERENCES IN TARGET LANGUAGES.  13:A63-A63. 2010
• Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications..  11:1061-1069. 2008
• PCV5 POTENTIAL COST SAVINGS FROM ACUTE CORONARY SYNDROME TREATMENT IMPROVEMENTS.  8:262-262. 2005
• Medical care costs associated with postmenopausal estrogen plus progestogen therapy..  7:544-553. 2004
• POS5 ECONOMIC EVALUATION OF SHORT-TERM NON-VERTEBRAL FRACTURE-RELATED COSTS AMONG OSTEOPOROSIS TREATMENTS.  7:297-297. 2004
• PHB6 Health Care Use in Women Age 45 And Older.  1:64-65. 1998
• PCR118 Cross-Sectional Measurement Properties of the Physical Distancing Scale COVID-19 (PDS-C19) Self- and Observer-Reported Measure of Physical Distancing Behaviors to Avoid COVID-19 in Adults, Children, and Caregivers.  26:s471-S471.
• PREDICTING HIGH-COST DIABETES PATIENTS: AN ANALYSIS OF COMMERCIALLY-INSURED POPULATION 2023
• PREDICTORS OF PEDIATRIC EMERGENCY DEPARTMENT (ED) VISITS FOR THE ACUTE AMBULATORY CARE SENSITIVE CONDITIONS (ACSC) 2023
• RISK FACTORS ASSOCIATED WITH REPEAT PEDIATRIC ASTHMA VISITS TO EMERGENCY DEPARTMENTS 2023
• THE IMPACT OF NEIGHBORHOOD FACTORS ON PEDIATRIC ED VISITS FOR AMBULATORY CARE SENSITIVE CONDITIONS 2023
• HEALTH EQUITY CONSIDERATIONS IN MINORITY GROUPS WITH TYPE 1 AND 2 DIABETES IN THE COVID-19 ERA: CARE UTILIZATIONS AND COSTS 2022
• IS ADDING RIBOCICLIB TO FULVESTRANT COST-EFFECTIVE IN TREATING POST-MENOPAUSAL WOMEN WITH HR+/ HER2-ADVANCED BREAST CANCER - A US PAYER PERSPECTIVE COST-UTILITY ANALYSIS 2022
• IS ADDING RIBOCICLIB TO FULVESTRANT COST-EFFECTIVE IN TREATING POST-MENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER - A US PAYER PERSPECTIVE COST-UTILITY ANALYSIS 2022
• EVALUATION OF TUCATINIB FOR HER2-POSITIVE BREAST CANCER PATIENTS WITH BRAIN METASTASES: A UNITED STATES-BASED COST-EFFECTIVENESS ANALYSIS 2021
• LIPOSOMAL BUPIVACAINE AND INPATIENT HOSPITAL COSTS AFTER COLORECTAL SURGERY 2021
• NEONATAL ABSTINENCE SYNDROME INCIDENCE RATE, CLINICAL CHARACTERISTICS & HEALTHCARE RESOURCE UTILIZATION IN TEXAS DURING 2006-2017 2021
• COST-EFFECTIVENESS OF RIBOCICLIB PLUS ENDOCRINE THERAPY IN TREATING PREMENOPAUSAL OR PERIMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN THE UNITED STATES 2020
• ECONOMIC EVALUATION OF EPIDERMAL GROWTH FACTOR RECEPTOR - TYROSINE KINASE INHIBITOR (EGFR-TKI) DRUGS IN NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT: A SYSTEMATIC REVIEW OF RECENT STUDIES 2020
• COST-EFFECTIVENESS ANALYSIS OF ERENUMAB VERSUS TOPIRAMATE FOR PATIENTS WITH CHRONIC MIGRAINES TO IDENTIFY THE COST-EFFECTIVE PRICE THRESHOLD IN GREECE 2019
• ESTIMATING QUALITY-ADJUSTED LIFE YEARS (QALYS) THROUGH QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (QTWIST) IN RCTS: AN ALTERNATIVE TO ECONOMIC MODELLING 2019
• BUDGET IMPACT ANALYSIS OF NIRAPARIB AND OLAPARUB AS MAINTENANCE THERAPY FOR PLATINUM SENSITIVE, RECURRENT OVARIAN CANCER IN THE US 2018
• COST-EFFECTIVENESS OF NIRAPARIB AND OLAPARIB AS MAINTENANCE THERAPY FOR PATIENTS WITH PLATINUM SENSITIVE < RECURRENT OVARIAN CANCER 2018
• RAPID ESTIMATION OF SMOKING-ATTRIBUTABLE MORTALITY AND ECONOMIC COSTS 2018
• EPIDEMIOLOGY AND ECONOMIC BURDEN OF SYSTEMIC SCLEROSIS - A SYSTEMATIC REVIEW 2017
• COMPARISON OF DATA TO DECISION MODELS FOR A DATA CONSORTIA 2016
• UTILIZATION PATTERN OF PRESCRIPTION PAIN MEDICATION AMONG ADULTS WITH DIABETES MELLITUS 2016
• A Bayesian Framework To Estimate The Cost Of Care For Renal Disease Patients With And Without A Usual Source Of Care Provider 2015
• Effects of Overweight and Obesity on Health service use and expenditures among U.S. adults with Chronic renal disease 2015
• Moral hazard and health insurance: examining the role of private vs. Public insurance in prostate cancer screening, prostate cancer diagonosis and patient satisfaction with prostate cancer care 2015
• DO CHILDREN WITH SPECIAL NEEDS RECEIVING CARE COORDINATION HAVE GREATER ACCESS TO PRIMARY CARE? 2014
• ARE DIFFERENT SPANISH VERSIONS OF PRO MEASURES NECESSARY? THE CASE STUDY OF THE PEDSQL (TM) 4.0 GENERIC CORE SCALES 2011
• A COMPARISON OF DAILY AVERAGE SUPPLY (DASUP) OF OXYCODONE AND OXYMORPHONE LONG-ACTING ORAL TABLETS 2011
• ECONOMIC IMPACT OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG PATIENTS TAKING OPIOID ANALGESICS 2011
• PAYER-RATED VALUE OF PAIN IMPROVEMENT IN CASTRATION-RESISTANT PROSTATE CANCER: TRADEOFFS BETWEEN SURVIVAL, PAIN AND ANALGESIC USE 2011
• USE OF SECONDARY DATA SOURCES TO ESTIMATE INPATIENT COSTS AND PAYMENTS FOR ACUTE CORONARY SYNDROME 2011
• COST-EFFECTIVENESS OF ROSUVASTATIN 10 MG IN THE REDUCTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS AT RISK OF CARDIOVASCULAR DISEASE 2010
• COST-EFFECTIVENESS OF ROSUVASTATIN 20 MG IN SECONDARY-PREVENTION PATIENTS IN THE UNITED STATES 2010
• ECONOMIC BURDEN OF ATHEROSCLEROSIS AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS 2009
• DIFFERENCES IN TREATMENT COSTS AND RESOURCE UTILIZATION AMONG COPD PATIENTS TREATED WITH ALBUTEROL MDI OR LEVALBUTEROL MDI 2008
• INCIDENCE OF INJURY AND COST OF CARE FOR PATIENTS SEEKING EMERGENT CARE FOR EPILEPSY IN A UNITED STATES MANAGED CARE SETTING 2008
• Rosuvastatin is more cost-effective compared to atorvastatin and simvastatin for hyperlipidemia management in high-risk patients in routine clinical practice 2006
• Summary of hospital logistics associated with intravenous patient-controlled analgesia (IV PCA) for acute postoperative pain management 2005
• Cost-effectiveness of tamsulosin, doxazosin and terazosin in the treatment of benign prostatic hyperplasia 2003

Identity

International Standard Serial Number (ISSN)

• 1098-3015